#TEMPEST THERAPEUTICS REGISTRATION#

Statements that are not historical facts are forward-looking statements. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as вЂњmay,вЂќ вЂњwill,вЂќ вЂњshould,вЂќ вЂњwould,вЂќ вЂњexpect,вЂќ вЂњanticipate,вЂќ вЂњplan,вЂќ вЂњlikely,вЂќ вЂњbelieve,вЂќ вЂњestimate,вЂќ вЂњproject,вЂќ вЂњintend,вЂќ and other similar expressions. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Millendo, as well as assumptions made by, and information currently available to, management of Millendo. This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the вЂњSecurities ActвЂќ)) concerning Millendo, Tempest, the proposed transaction and other matters.

#TEMPEST THERAPEUTICS REGISTRATION#

This document will not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Tempest is headquartered in South San Francisco and supported by notable healthcare investors.В More information about Tempest can be found on the companyвЂ™s website at Non-solicitation Tempest is also developing an orally-available inhibitor of TREX-1 designed to control activation of the cGAS/STING pathway, an innate immune response pathway involved in the development of anti-tumor immunity. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. The companyвЂ™s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARО±, respectively. Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. For more information, please visit About Tempest Therapeutics

Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need.

Millendo Therapeutics is a biopharmaceutical company previously primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Following the closing of the merger, the combined company will be renamed Tempest Therapeutics and shares will begin trading with the open of the market on Monday, JuneВ 28, 2021 under the ticker вЂњTPST.вЂќ The closing of the merger is anticipated to take place on or around Friday, June 25, 2021. The stockholders voted in favor of all proposals at the Special Meeting, including to approve the proposed merger between the companies. (Nasdaq: MLND) (вЂњMillendoвЂќ), announced today the results for the proposals voted upon by Millendo stockholders at a Special Meeting on June 22, 2021. (вЂњTempestвЂќ), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics, Inc. and ANN ARBOR, Mich., J(GLOBE NEWSWIRE) - Tempest Therapeutics, Inc.

Tempest therapeutics